Definition
An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.
Description
Clindamycin is a semisynthetic lincosamide antibiotic that has largely replaced lincomycin due to an improved side effect profile. Clindamycin inhibits bacterial protein synthesis by binding to bacterial 50S ribosomal subunits. It may be bacteriostatic or bactericidal depending on the organism and drug concentration.
Top Gene Interactions
Related Pathways
General Information
- Metabolism: Hepatic Route of Elimination: Approximately 10% of the bioactivity is excreted in the urine and 3.6% in the feces; the remainder is excreted as bioinactive metabolites. Half Life: 2.4 hours
- Uses/Sources: Used to treat infections with anaerobic bacteria but can also be used to treat some protozoal diseases, such as malaria. It is a common topical treatment for acne and can be useful against some methicillin-resistant Staphylococcus aureus (MRSA) infections. [Wikipedia] For the treatment of serious infections caused by susceptible anaerobic bacteria, including Bacteroides spp., Peptostreptococcus, anaerobic streptococci, Clostridium spp., and microaerophilic streptococci. May be useful in polymicrobic infections such as intra-abdominal or pelvic infections, osteomyelitis, diabetic foot ulcers, aspiration pneumonia and dental infections. May also be used to treat MSSA and respiratory infections caused by S. pneumoniae and S. pyogenes in patients who are intolerant to other indicated antibiotics or who are infected with resistant organism. May be used vaginally to treat vaginosis caused by Gardnerella vaginosa. Clindamycin reduces the toxin producing effects of S. aureus and S. pyogenes and as such, may be particularly useful for treating necrotizing fasciitis. May be used topically to treat acne.
- Symptoms: Orally and parenterally administered clindamycin has been associated with severe colitis (pseudomembranous colitis) which may result in patient death. Use of the topical formulation of clindamycin results in absorption of the antibiotic from the skin surface. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin.
- Route of Exposure: Oral; topical; parenteral (intramuscular, intravenous). Rapidly absorbed after oral administration with peak serum concentrations observed after about 45 minutes. Absorption of an oral dose is virtually complete (90%) and the concomitant intake of food does not appreciably modify the serum concentrations; serum levels have been uniform and predictable from person to person and dose to dose. Clindamycin does not penetrate the blood brain barrier.
Clindamycin Interacts with Diseases
Disease | Inference Score | References/Inference Genes |
Spondyloepimetaphyseal Dysplasia, Missouri Type | 5.93 |
|
Typhoid fever | 5.88 |
|
Oropharyngeal Neoplasms | 5.73 |
|
Eosinophilia-Myalgia Syndrome | 5.53 |
|
Berylliosis | 5.15 |
|
Sarcoidosis | 4.99 |
|
Narcolepsy | 4.71 |
|
Visceral leishmaniasis | 4.6 |
|
Membranous glomerulonephritis | 4.52 |
|
Crohn's disease | 4.34 |
|
Multiple sclerosis | 4.34 |
|
Diabetes Mellitus, Type 1 | 4.32 |
|
Ulcerative colitis | 4.14 |
|
Pancreatitis | 4.09 |
|
Nephrotic syndrome | 4.07 |
|
Systemic lupus erythematosus | 4.04 |
|
Lymphoma, Non-Hodgkin | 4.02 |
|
Angioedema | 3.95 |
|
Allergy | 3.91 |
|
Urticaria | 3.81 |
|